Esperion Therapeutics, Inc ESPR

Moshkelgosha

Market Cap: 370 M Shares Outstanding: 28.2M Average Trading Volume (10 days): 451K Shares Short: 28 M Short Interest(%): 31.4% Days to cover: 15.4 Change in Short Interest: -35 Ownership Breakdown: Institutions: 93.1% General Public: Hedge Funds: 5.6% Individual insiders: 1.3% Sum: 100% Option profile: Total OI: Put Call Ratio:0.63 Put OI: Call OI: Highest...

SaTLla101

I think ESPR could start to get interested in this level . - After a long decline from the peak ($ 40) this year, on 27/1/2021, we are now witnessing a consolidation in the price level. - I do not look at fundamental information, only technical data . Indicators : * EMA21 is the purple line * EMA9 is the green line * Consolidation at Slow Stochastic * RSI...

jarc56

On the lookout for squeeze as short interest is high

dread003111

ESPR

Champion-Vibe

MID-TERM: Holding support with classic bullish divergence. High short float. (not financial advice)

Legalizedhustler

Not financial advice. Support the legalizedhustler #hustlabynature Want individual assessments of stocks or crypto Let me know. Let's make a deal.

abel11

Looks like the pattern is completing, now i expect either a total reversal or a consolidation. All these options are bullish. Comment what you think below. Don't forget to click the like if you do. Thank you.

British-Investors

Double bottom chart. Earnings being announced 23rd February

HorizontalPriceLevelsTrading

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment. If you...

AlexeyCryptoMan

$47 !!! within three days

Mike_y

Broke out of the falling wedge and is now setting up with an inverse head and shoulders worth watching for a play to $53

TradingMula

Risk $1 for $9 to target $40

BuySellMarketMaker

In February 2020, both Nexletol and Nexlizet were approved as oral treatments to lower LDL-C. Bempedoic acid remains in clinical trials of its efficacy in risk reduction for cardiovascular disease. Esperion shares peaked last February, after the FDA approvals, but since then, the stock has declined. Shares are down 65% since their peak. (tipranks.com) Analyst...

AlTorress

This indicator may be signaling that ESPR's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. Tickeron's A.I.dvisor backtested 94 similar cases where ESPR's Momentum Indicator exceeded 0, and 81 of them led to a successful outcome. Odds of Success: 86%....

shishoo

Long term wave count with potential entry and exit zones

AlTorress

This indicator may be signaling that ESPR's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. Tickeron A.I.dvisor backtested 96 similar cases where ESPR's Momentum Indicator exceeded 0, and 84 of them led to a successful outcome. Odds of Success: 88%....

Will_Wong

Sweet 3 of 3 next. Target $110 which is almost 4 times the current price.

Bullishcharts

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul...